Intra Cellular Therapies, Inc. ITCI
We take great care to ensure that the data presented and summarized in this overview for Intra-Cellular Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITCI
View all-
Vanguard Group Inc Valley Forge, PA9.61MShares$737 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$485 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$285 Million1.37% of portfolio
-
Jpmorgan Chase & CO New York, NY3.44MShares$264 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$230 Million2.8% of portfolio
-
Invesco Ltd. Atlanta, GA2.94MShares$225 Million0.04% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.47MShares$190 Million2.83% of portfolio
-
Norges Bank Oslo, Q81.94MShares$149 Million0.02% of portfolio
-
State Street Corp Boston, MA1.8MShares$138 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY1.72MShares$132 Million0.1% of portfolio
Latest Institutional Activity in ITCI
Top Purchases
Top Sells
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Transactions at ITCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,513
+3.52%
|
$688,721
$17.57 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,713
-2.08%
|
$1,680,762
$74.59 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,713
+2.04%
|
$386,121
$17.57 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
28,680
-2.61%
|
$2,122,320
$74.46 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,680
+2.54%
|
$487,560
$17.57 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
39,380
-1.78%
|
$2,953,500
$75.03 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,380
+3.43%
|
$669,460
$17.57 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
53,013
-1.19%
|
$4,028,988
$76.7 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,013
+4.51%
|
$901,221
$17.57 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,714
-38.65%
|
$1,403,550
$75.08 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+27.88%
|
$673,704
$36.89 P/Share
|
|
Jun 28
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
262
+0.22%
|
$17,816
$68.49 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 1.03M shares |
|---|---|
| Grant, award, or other acquisition | 81.9K shares |
| Open market or private sale | 1.06M shares |
|---|